DCRI’s CEC Group Contributes to AHA Late-Breakers
Through new ways of working and collaborations across Duke, the DCRI’s Clinical Events Classification group is continuously improving on its processes.
AHA 2020: RIVER Shows Rivaroxaban Safe for Patients with Bioprosthetic Valves
The study, which is the only randomized trial testing rixaroxaban in this patient population, builds on previous evidence established by the DCRI-led ROCKET-AF and ARISTOTLE studies.
AHA 2020: GALACTIC-HF Finds Investigational Therapy to be Effective
Patients assigned to the treatment, omecamtiv mecarbil, experienced a statistically significant difference in a composite endpoint of time to cardiovascular death or time to first heart failure event.
PROVIDE-HF Finds Early Improvements in Quality of Life in Patients with Heart Failure Treated with Sacubitril/Valsartan
By evaluating patient-reported and electronic health record data, the pragmatic clinical study adds important real-world evidence to inform clinical practice.
DCRI Selected as U.S. Coordinating Center for NIH ACTIV-1 Trial
The DCRI has received $44 million in funding to examine whether three immune modulators help prevent overactive immune response in moderate or severe cases of COVID-19.
TCT 2020: New One-year Follow Up Results Shed Light on Optimal Care After PCI
New results from the one-year follow up of the DEFINE-PCI trial shed light on how to optimize care for patients who have undergone percutaneous coronary intervention (PCI). The results, presented as late-breaking science by DCRI’s Manesh Patel, MD, were shared virtually Thursday at the 2020 Transcatheter Cardiovascular Therapeutics (TCT) Connect.
Clinical Trials ‘System is Working,’ Hernandez Says
Recent pauses of COVID-19 vaccine trials show that the clinical trials system is working, writes DCRI Executive Director Adrian Hernandez, MD, MHS, in an opinion piece published today by STAT News. Hernandez authored the piece in response to pauses of three vaccine trials: First AstraZeneca’s study was put on hold in September, and this week, both Johnson & Johnson and the NIH paused trials.
DCRI, UNC Center for Health Equity Research, and Partners Receive $80 Million Award from NIH to Help Expand COVID-19 Testing
The nationwide program aims to build innovative and sustainable solutions to expand test access and uptake in underserved and vulnerable communities.
DCRI Launches First Direct-to-Family Study to Improve Medication Dosing and Adherence in Children and Teens with Lupus
The clinical study's home-based design combines on-site nursing visits and mobile technology to embed research into patients' lives.
At DCRI, Collaborations Lead to Better Evidence
Building on DCRI’s strong history in building cardiovascular evidence, researchers at the Institute with a wide range of expertise are also considering how cardiovascular disease factors into other